Modafinil: Difference between revisions

Line 2:

'''Modafinil''' (also known by the brand names '''Provigil''', '''Alertec''', '''Modavigil''', ~~among~~ others) is a [[psychoactive class::eugeroic]] substance of the [[chemical class::benzhydryl]] class that produces [[wakefulness|wakefulness-promoting]] and [[stimulant]] effects when [[administered]]. It is commonly used to enhance cognition, reduce fatigue, and increase alertness in both medical and non-medical contexts.

'''Modafinil''' (also known by the brand names '''Provigil''', '''Alertec''', '''Modavigil''', and others) is a [[psychoactive class::eugeroic]] substance of the [[chemical class::benzhydryl]] class that produces [[wakefulness|wakefulness-promoting]] and [[stimulant]] effects when [[administered]]. It is commonly used to enhance cognition, reduce fatigue, and increase alertness in both medical and non-medical contexts.

Modafinil is approved by the U.S. Food and Drug Administration for the treatment of obstructive sleep apnea, shift work sleep disorder and narcolepsy.<ref>Provigal (Manufacturer's Website) | http://www.provigil.com/</ref> However, studies have shown that modafinil may also be useful off-label for alleviating the symptoms of depression,<ref>Modafinil augmentation of selective serotonin reuptake inhibitor therapy in MDD partial responders with persistent fatigue and sleepiness (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/17729016</ref>, bipolar disorder,<ref>A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/17671288</ref> Parkinson's disease,<ref>Neuroprotective effects of modafinil in a marmoset Parkinson model: behavioral and neurochemical aspects (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/16940766</ref> seasonal depressive disorder,<ref>PubMed - Modafinil treatment in patients with seasonal affective disorder/winter depression: an open-label pilot study (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/15306145</ref> ADHD,<ref>Modafinil improves symptoms of attention-deficit/hyperactivity disorder across subtypes in children and adolescents (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/18280848</ref> and various other conditions which have fatigue as a symptom.

@@ Line 2: / Line 2: @@
 {{SubstanceBox/Modafinil}}
-'''Modafinil''' (also known by the brand names '''Provigil''', '''Alertec''', '''Modavigil''', among others) is a [[psychoactive class::eugeroic]] substance of the [[chemical class::benzhydryl]] class that produces [[wakefulness|wakefulness-promoting]] and [[stimulant]] effects when [[administered]]. It is commonly used to enhance cognition, reduce fatigue, and increase alertness in both medical and non-medical contexts.
+'''Modafinil''' (also known by the brand names '''Provigil''', '''Alertec''', '''Modavigil''', and others) is a [[psychoactive class::eugeroic]] substance of the [[chemical class::benzhydryl]] class that produces [[wakefulness|wakefulness-promoting]] and [[stimulant]] effects when [[administered]]. It is commonly used to enhance cognition, reduce fatigue, and increase alertness in both medical and non-medical contexts.
 Modafinil is approved by the U.S. Food and Drug Administration for the treatment of obstructive sleep apnea, shift work sleep disorder and narcolepsy.<ref>Provigal (Manufacturer's Website) | http://www.provigil.com/</ref> However, studies have shown that modafinil may also be useful off-label for alleviating the symptoms of depression,<ref>Modafinil augmentation of selective serotonin reuptake inhibitor therapy in MDD partial responders with persistent fatigue and sleepiness (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/17729016</ref>, bipolar disorder,<ref>A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/17671288</ref> Parkinson's disease,<ref>Neuroprotective effects of modafinil in a marmoset Parkinson model: behavioral and neurochemical aspects (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/16940766</ref> seasonal depressive disorder,<ref>PubMed - Modafinil treatment in patients with seasonal affective disorder/winter depression: an open-label pilot study (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/15306145</ref> ADHD,<ref>Modafinil improves symptoms of attention-deficit/hyperactivity disorder across subtypes in children and adolescents (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/18280848</ref> and various other conditions which have fatigue as a symptom.